jabire2389.blogspot.com
After finding that its tuberculosis drug was safe in a singlwe dose twoyears ago, the Rockville biotech has now begun dosing the firsty of three groups of volunteers in a first-phaswe trial to test the drug’s safety when taken on a dailt basis. The drug, which has earned fast-track and orphan drug statuse from the Food andDrug Administration, is aimed at fightinf drug-sensitive and drug-resistant strains of tuberculosis. The at the is conductintg the study through a contract with DynporfVaccine Co. LLC. The trial will take placew at the Quintiles Transnational Phase 1 facility inOverland Park, the same location as the first trials in 2007.
In Sequella is in its final stage of testing a skin patcnh todiagnose tuberculosis, a product it hopees to start selling to developing countries by earlyg next year, and recently receive more than $2.3 million in NIH grants to develop two more TB still in preclinical stages.
No comments:
Post a Comment